ASCO 2015 Highlights

CD19 CAR T Cells Induce Potent Responses and Control CNS Leukemia in Relapsed ALL

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

CLL – Clinical Poster Session: Friday, June 10

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

Duration of TKI Treatment and Duration of Deep Molecular Response Affect Relapse-Free Survival in CML

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

Higher-Dose Daunorubicin Is Effective in Patients with AML Who Harbor FLT3-ITD Mutations

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

Ibrutinib plus Bendamustine and Rituximab (BR) in Previously Treated CLL/SLL: 2-Year Follow-Up Data from the HELIOS Study

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

Innovative Therapies in CLL: Saturday, June 11

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

Length of Time on Treatment Observed in Ibrutinib Clinical Trials Is Reproducible After Assessment of Real-World Data

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

Outcomes Associated with Conventional Salvage Therapy in Patients with Refractory or Relapsed AML and IDH1/IDH2 Mutations

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

Overall Survival Benefit in Relapsed and Refractory B-Cell ALL Patients Receiving Inotuzumab Ozogamicin

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

Presidential Symposium: Friday, June 10

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

Page 162 of 330